Facebook Target Reduced and 4 Must-See Stock Analyses
Limited Brands, Inc. (NYSE:LTD): Cowen said Limited Brands Inc.’s haggard performance versus the S&P 500 Retail Index is unjustified and raised their estimates citing a strong same store sales momentum leading to a potential guidance raise by the company. Shares are Outperform rated.
Tyco International Ltd. (NYSE:TYC): Cowen said Tyco International Ltd. retains the key traits they had before their spin-off including high market shares, recurring sales mix, and big cost reduction potential. The firm said Tyco appears to be on track for solid organic growth and believes their focused portfolio could make them an outside takeover candidate. Shares are Outperform rated.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Facebook, Inc. (NASDAQ:FB): Oppenheimer reduced their target on Facebook because the firm believes that the shift towards mobile Internet is occurring much more quickly than predicted. As a result of the changing landscape, the firm lowered their 2012 and 2013 revenue estimates on the company to below consensus levels, but they maintain an Outperform rating on their stock.
Acuity Brands, Inc. (NYSE:AYI): Oppenheimer believes that Acuity Brand, Inc.’s second quarter revenue may be light, but the firm recommends that “investors be alert for a possible window of opportunity.” The company anticipates that the company’s earnings per share can grow significantly over the next several years, however, they maintain a Perform rating on the shares.
Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX): Baird said Allscripts Healthcare Solutions, Inc. has not commented on speculation, they have hired an advisor to speak with private equity firms and believe that the possibility is feasible. The firm said their leveraged buyout analysis easily supports an attractive deal and said investors should balk at anything less than $18 per share. Shares are Outperform rated and the price target is raised from $15 to $17 .
Don’t Miss: Xstrata Backs This New Buyout Bid.